Bryan Johnson· Author
On September 28th, I decided to stop rapamycin, ending almost 5 years of experimentation with this molecule for its longevity potential.
Loading…
We can't find evidence that holds up here. Proponents are reasoning from mechanism or analogy rather than direct human data, and the most credible skeptics raise objections we can't dismiss.
On September 28th, I decided to stop rapamycin, ending almost 5 years of experimentation with this molecule for its longevity potential.
Every Sunday: the week’s new conflicts and verdict changes — and nothing else.
Native comments, Twitter mentions, and Reddit threads about this claim — surfaced together so the conversation isn't fragmented across platforms.
The "high risk" framing here is the right call. I've had three patients ask about rapa this month and none of them grasped the immunosuppression tradeoff until I walked them through it.
The PEARL trial framing in the dossier is the clearest writeup I've seen for a non-specialist. Worth linking from the AMA pages too.
I'm on 6mg/week, year two. Tracking IL-6, fasting glucose, lipids. Happy to share the spreadsheet if Whalespan wants longitudinal user data.
The dosing variance across the advocate camp is staggering. 3mg, 5mg, 8mg, biweekly, weekly… brief is right that "monitor or specialist only" is the responsible read.
Despite the immense potential from pre-clinical trials, my team and I came to the conclusion that the benefits of lifelong dosing of Rapamycin do not justify the hefty side-effects (intermittent skin/soft tissue infections, lipid abnormalities, glucose elevations, and increased resting heart rate).
In September I stopped Rapamycin, based on concerns around its metabolic side-effects observed in my lab results (including increased cholesterol, blood sugar and RHR); the data here showed Rapamycin increased biological aging according to two clocks, while ineffective according to the others.
Despite the immense potential from pre-clinical trials, my team and I came to the conclusion that the benefits of lifelong dosing of Rapamycin do not justify the hefty side-effects (intermittent skin/soft tissue infections, lipid abnormalities, glucose elevations, and increased resting heart rate).
On September 28th, I decided to stop rapamycin, ending almost 5 years of experimentation with this molecule for its longevity potential.
it was messing with my lipids no way uh yep so a few side effects uh lipids were messed up blood glucose resting heart rate was increased and I had some small tissue infections holy crap it is a grotesqually catabolic substance is point
For example I'd have cankers in my mouth or maybe a wound wouldn't heal fast enough My blood report showed that I had cholesterol disruptions My blood glucose spiked a little bit And then perhaps the thing that was most painful for me it increased my resting heart rate
Now in doing this I have been working with a team of medical professionals trying to build the world's best health protocol Now in doing this we were trying one of the world's most promising experimental drugs for slowing down my speed of aging Turns out I was actually accelerating my speed of aging
And sure enough without it my blood glucose dropped my cholesterol corrected soft tissue infections went away The side effects were in fact from rapamy
One is I took one of the more promising drugs in the anti-aging world called rapamy. I did it for several years meticulously measuring my levels. It turns out that drug accelerate speed of aging. Great irony. Really fun. Now this is not conclusive on that drug. It may be the case that in me it had that effect. There may be other things we weren't measuring but still in that one narrow marker it was accelerating how fast I was aging.
I did however notice side effects. For example, I'd have cankers in my mouth or maybe a wound wouldn't heal fast enough. My blood report showed that I had cholesterol disruptions. My blood glucose spiked a little bit. The thing that was most painful for me, it increased my resting heart rate
Rapamycin extends median and maximum lifespan in mice across multiple lab strains and dosing protocols.
Rapamycin will extend human lifespan by 5+ years at standard weekly dosing.
Weekly rapamycin dosing in healthy adults shows favorable safety and immune markers in early observational data.
Chronic low-dose rapamycin imposes an immune trade-off that outweighs the longevity hypothesis for most healthy adults.
mTORC1 inhibition is the mechanistic backbone for rapamycin's healthspan effects in mammals.
The PEARL trial showed an acceptable 48-week safety profile in healthy adults on weekly rapamycin.